Hypothyroidism in Pregnancy

Physiologic changes during pregnancy

Early in pregnancy estrogen promotes production of a more highly sialylated T_4 -binding globulin isoform that is less rapidly degraded (reduced hepatic clearance), resulting in an increased serum T_4 -binding globulin and T_4 concentrations. The test results that change significantly are those that are influenced by serum TBG concentration. These include total thyroxine (TT₄), total triiodothyronine (TT₃), and resin triiodothyronine uptake (RT₃U).

Although a transient decrease in serum free T₄, followed by a rise in TSH may occur, this is usually not seen with routine thyroid testing. A high circulating HCG level in the first trimester leads to HCG cross reactivity with the TSH receptor, prompting a temporary increase in a T₄ and partial suppression of TSH.

The final physiologic change results from placental deiodination of maternal T_4 , which increases T_4 turnover. In addition, there is increased renal clearance of iodide. This alteration is associated with a noticeable increase in thyroid gland size in ~ 15% of women.

Maternal Status	тѕн	FT4	FTI	TT₄	TT ₃	RT₃U	
Pregnancy	No change	No change	No change	Increase	Increase	Decrease	
Hyperthyroidism	Decrease	Increase	Increase	Increase	Increase or no change	Increase	
Hypothyroidism	Increase	Decrease	Decrease	Decrease	Decrease or no change	Decrease	

Fetal thyroid development begins at 10-12 weeks gestation and is not complete until delivery. T_4 is not secreted until 18-20 weeks gestation.

TSH does not cross the placenta and only small amounts of T_4 and T_3 cross the placenta. TRH, iodine, and TSH receptor immunoglobulins do cross the placenta as do the thioamides, propylthiouracil (PTU) and methimazole.

T₄ is critical for many aspects of brain development including neurogenesis, neuronal migration, axon and dendrite formation, myelination, synaptogenesis, and neurotransmitter regulation.

- Studies in partially thyroidectomized (parathyroid spared) Sprague-Dawley rats demonstrate decreased levels
 of glial fibrillary acidic protein, suggesting delayed astrocytic differentiation, which were only apparent after
 onset of fetal T₄ secretion.
- Studies in hypothyroid induced Sprague Dawley rats have also demonstrated decreased expression of synaptotagmin related gene 1 protein, which is involved in the regulation of neurotransmission. Upon in vitro exposure for 24 hours to T₄, cerebellar granule cells srg1 mRNA was rapidly upregulated.

Impact of maternal hypothyroidism and/or hypothyroxinemia

The incidence of maternal hypothyroidism in the U.S. during pregnancy is $\sim 2.5\%$. The prevalence of subclinical hypothyroidism in the US adult population is ~ 4 to 8.5% in those without known thyroid disease.

The severity, timing of onset and duration, as well as the postnatal management all influence fetal and neonatal brain development.


The most severely affected infants have neurologic cretinism, manifest as mental retardation (IQ ~ 29) and impaired gait and motor function. These abnormalities have been associated with maternal T_4 but not T_3 levels during pregnancy. Untreated hypothyroidism is associated with several complications including preeclampsia and low birth weight as well as abruptio placentae and an increased risk of spontaneous abortion and perinatal mortality. The etiology of low birth weight was medically indicated preterm delivery, Preeclampsia, or placental abruption. In 1999, Klein retrospectively screened 25,000 mothers for hypothyroidism in New England. TSH concentrations \geq 97.7 percentile was considered to indicate hypothyroidism. The women formed three groups: 14 women with previously diagnosed hypothyroidism who had been treated before and throughout pregnancy; 48 women whose hypothyroidism was not treated during pregnancy; and 124 matched controls whose TSH was < 97.7 percentile. Compared with children of treated mothers (IQ 111±3.3), children of untreated mothers had a lower IQ (100±2.2, p = 0.04) when measured at 8 years of age.

In 1999, Pop et al., prospectively assessed mental and psychomotor development in 125 (63 cases, 62 controls) 10-month old infants living in The Netherlands, an iodine sufficient country. They found that if the mother's free- T_4 was in the lowest 10th percentile at 12 weeks gestation, the infants had an increased risk of delayed psychomotor development (RR 5.8). Two years later, 115 subjects were available for followup (57 cases, 58 controls).

	Cases	Controls	Ρ	95% CI				
One year								
Mental, mean (SD)	95 (15)	105 (14)	0.004	4-16				
Motor, mean (SD)	91 (15)	99 (14)	0.02	3-12				
Two years								
Mental, mean (SD)	98 (15)	106 (14)	0.02	4-12				
Motor, mean (SD)	92 (16)	102 (16)	0.005	6-16				

Differences on the Bayley mental (MDI) and motor (PDI) subscales - assessed both at 1 and 2 years - of 57 children of mothers with hypothyroxinaemia (an $TT4 \le 10$ th percentile, cases) during early gestation and 58 children of mothers with an fT4 between the 50th and 90th percentiles controls (*t*-test, two tailed). *Clinical Endocrinology*, **59**, p. 285.

Scatter diagram of a linear regression of maternal fT4 concentrations of the cases (fT4 at 12 weeks' gestation below the 10th percentile, n=57) with, at 2 years of age, mental (top, $R^2 = 0.13$, P = 0.006) and psychomotor (bottom, $R^2 = 0.23$, P = 0.001) scores of the Bayley scale. *Clinical Endocrinology*, **59**, p. 286.



<u>Diagnosis</u>

- Free T₄ is the preferred test because it is relative maternal hypothyroxinemia, not a mild TSH elevation, which
 puts the fetus at risk.
- If the FT₄ is not available, the free thyroxine index (FTI) can be calculated where FTI = RT₃U * TT₄. In general, measurement of FT₃ is usually only pursued in patients with thyrotoxicosis with a suppressed TSH and normal FT₄. Elevated FT₃ indicates T₃ toxicosis, which may occur before excessive FT₄ production develops.

Treatment

The World Health Organization recommends 200 µg/day iodine intake for pregnant and lactating women.

Smallridge and Ladenson (2001) reviewed four case series in which serum TSH increased by 58%. In their analysis, the mean L-thyroxine dose increased from 117 μ g to 150 μ g. Lazarus (Thyroid, 2002) recommended an increase on the order of 50 to 100 μ g LT4/day.

Alexander, NEJM 2004, identified 19 women with primary hypothyroidism from the outpatient endocrine clinics at Brigham and Women's Hospital in Boston, MA. They sought to delineate the timing and pattern of increased thyroid hormone requirement during pregnancy in order to determine appropriate recommendations for preventing first trimester hypothyroidism. Measurements were made every two weeks in the first trimester and monthly thereafter. Six women were initially maintained at a greater degree of suppression due to a history of thyroid cancer. Subjects were instructed not to ingest vitamins or products containing calcium, iron, or soy within four hours of their Levothyroxine. Serum thyrotropin levels increased during the first 10 weeks of gestation prompting an increase in the LT4 dose in 85% of the group. The dose of LT4 was quickly increased from 6 to 16 weeks and then remained the same.

Variable	Week of Gestation					P Value by ANOVA	P Value by Newman–Keuls Test					
	Before Pregnancy	10	20	30	38		Before Pregnancy vs. 10 wk	Before Pregnancy vs. 20 wk	Before Pregnancy vs. 38 wk	10 wk vs. 20 wk	20 wk vs. 38 wk	30 wk vs 38 wk
Thyrotropin (μU/ml)	1.0±1.14	4.2±3.8	2.3±3.2	1.3±1.5	1.0±0.9	0.002	<0.01	0.29	0.99	0.04	0.28	0.93
Free thyroxine index	8.8±1.2	7.8±1.8	8.9±1.5	8.5±1.7	8.5±1.8	0.33	NA	NA	NA	NA	NA	NA
Thyroid hormone- binding ratio	1.0±0.1	0.8±0.1	0.7±0.05	0.6±0.06	0.6±0.1	<0.001	<0.001	<0.001	<0.001	<0.001	0.79	0.99
Thyroxine dose (fraction of dose before pregnancy)	1.00±0	1.29±0.25	1.48±0.18	1.48±0.15	1.47±0.17	<0.001	<0.001	<0.001	<0.001	<0.001	0.99	0.99
Estradiol (pg/ml)	55±24	1100±400	7000±2800	13,500±3500	20,400±4200	< 0.001	0.91	< 0.001	< 0.001	< 0.001	< 0.001	< 0.001

At 10 weeks gestation, the dose of LT4 has increased $29 \pm 25\%$ (p<0.001). At 20 weeks, the increase relative to baseline was 48 % (p < 0.001) and the dose remained stable thereafter. Based on these observations, it is suggested that women under treatment for hypothyroidism increase their dose of LT4 by 30% beginning the week pregnancy is confirmed.

It takes approximately 4 weeks for thyroxine therapy to alter TSH levels. Therefore, Levothyroxine (LT4) therapy should be adjusted at 4 weeks intervals until TSH levels are stable.

The incidence of congenital hypothyroidism is 1 per 4000 newborns. All 50 states offer screening for congenital hypothyroidism. If identified with the first few weeks of life, near normal growth and intelligence can be expected.

References

1. Smallridge RC, Ladenson PW. Hypothyroidism in pregnancy: consequences to neonatal health. *J Clin Endocrinol Metab.* 2001 Jun; 86(6):2349-53.

2. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 37, August 2002. (Replaces Practice Bulletin Number 32, November 2001). Thyroid disease in pregnancy. *Obstet Gynecol.* 2002 Aug; 100(2):387-96.

3. Sampson D, Pickard MR, Sinha AK, Evans IM, Leonard AJ, Ekins RP. Maternal thyroid status regulates the expression of neuronal and astrocytic cytoskeletal proteins in the fetal brain. *J Endocrin.* 2000; 167:439-45.

4. Potter GB, Facchinetti F, Beaudoin GM 3rd, Thompson CC. Neuronal expression of synaptotagmin-related gene 1 is regulated by thyroid hormone during cerebellar development. *J Neurosci.* 2001 Jun 15; 21(12):4373-80.

5. Lazarus JH. Epidemiology and prevention of thyroid disease in pregnancy. *Thyroid*. 2002 Oct; 12(10):861-5. Erratum in: *Thyroid*. 2003 Apr; 13(4):415.

6. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. *JAMA*. 2004 Jan 14; 291(2):228-38.

7. Klein RZ, Mitchell ML. Maternal hypothyroidism and cognitive development of the offspring. *Curr Opin Pediatr.* 2002 Aug; 14(4):443-6.

8. Haddow JE, Glenn EP, Allan WC, Williams JR, Knight GJ, Gagnon J, O'Heir CE, Mitchell ML, Hermos RJ, Waisbren SE, Faix JD, Klein RZ. *N Engl J Med.* 1999 Aug 19; 341 (8): 549-55.

9. Pop VJ, Brouwers EP, Vader HL, Vulsma T, van Baar AL, de Vijlder JJ. Maternal hypothyroxinaemia during early pregnancy and subsequent child development: a 3-year follow-up study. *Clin Endocrinol (Oxf)*. 2003 Sep; 59(3):282-8.

10. Kumar A, Singh R, Prasad S. Hypothyroidism during pregnancy. Int J Gynaecol Obstet. 2004 Mar; 84(3):252-3.

11. Alexander EK, Marqusee E, Lawrence J, Jarolim P, Fischer GA, Larsen PR. Timing and magnitude of increases in Levothyroxine requirements during pregnancy in women with hypothyroidism. *N Engl J Med.* 2004 Jul 15; 351(3):241-9.

Additional Reading

1. Dowling ALS, lannacone EA, Zoeller RT. Maternal hypothyroidism selectively affects the expression of neuroendocrinespecific Protein A messenger ribonucleic acid in the Proliferative zone of the fetal rat brain cortex. *Endocrin.* 2001; 142:390-9.

2. Lima FRS, Gervais A, Colin C, Izembart M, Neto VM, Mallat M. Regulation of microglial development: A novel role for thyroid hormone. *J Neurosci.* 2001 Mar 15; 21(6):2028-38

3. Martinez B, del Hoyo P, Martin MA, Arenas J, Perez-Castillo A, Santos A. Thyroid hormone regulates oxidative phosphorylation in the cerebral cortex and striatum of neonatal rats. *J Neurochem.* 2001 Sep; 78(5):1054-63.

4. Barradas PC, Vieira RS, De Freitas MS. Selective effect of hypothyroidism on expression of myelin markers during development. *J Neurosci Res.* 2001 Oct 15; 66(2):254-61.

5. Wong CC, Leung MS. Effects of neonatal hypothyroidism on the expressions of growth cone proteins and axon guidance molecules related genes in the hippocampus. *Mol Cell Endocrinol.* 2001 Nov 26; 184(1-2):143-50.

6. Sampson D, Pickard M, Evans I, Leonard A, Sinha A, Ekins R. Thyroid hormone regulates the expression of α -internexin in neurons in culture. *Neuroreport.* 2002. 13(3):273-6.

7. Evans IM, Pickard MR, Sinha AK, Leonard AJ, Sampson DC, Ekins RP. Influence of maternal hypothyroidism in the rat on the expression of neuronal and astrocytic cytoskeletal proteins in fetal brain. *J Endocrin.* 2002. 175:597-604

8. Pickard MR, Leonard AJ, Ogilvie LM, Edwards PR, Evans IM, Sinha AK, Ekins RP. Maternal hypothyroidism in the rat influences placental and liver glycogen stores: fetal growth retardation near term is unrelated to maternal and placental glucose metabolic compromise. *J Endocrinol.* 2003 Feb; 176(2):247-55.

9. Lavado-Autric R, Auso E, Garcia-Velasco JV, Arufe Mdel C, Escobar del Rey F, Berbel P, Morreale de Escobar G. Early maternal hypothyroxinemia alters histogenesis and cerebral cortex cytoarchitecture of the progeny. *J Clin Invest.* 2003 Apr; 111(7):1073-82.

10. Darbra S, Garau A, Balada F, Sala J, Marti-Carbonell MA. Perinatal hypothyroidism effects on neuromotor competence, novelty-directed exploratory and anxiety-related behaviour and learning in rats. *Behav Brain Res.* 2003 Aug 14; 143(2):209-15.

11. Sui L, Gilbert ME. Pre- and postnatal propylthiouracil-induced hypothyroidism impairs synaptic transmission and plasticity in area CA1 of the neonatal rat hippocampus. *Endocrinology*. 2003 Sep; 144(9):4195-203.

12. Gilbert ME, Paczkowski C. Propylthiouracil (PTU)-induced hypothyroidism in the developing rat impairs synaptic transmission and plasticity in the dentate gyrus of the adult hippocampus. *Brain Res Dev Brain Res.* 2003 Oct 10; 145(1):19-29.

13. Gilbert ME. Alterations in synaptic transmission and plasticity in area CA1 of adult hippocampus following developmental hypothyroidism. *Brain Res Dev Brain Res.* 2004 Jan 31; 148(1):11-8.

14. de Escobar GM, Obregon MJ, del Rey FE. Maternal thyroid hormones early in pregnancy and fetal brain development. Best Pract Res Clin Endocrinol Metab. 2004 Jun; 18(2):225-48. Review

15. van Tuyl M, Blommaart PE, de Boer PA, Wert SE, Ruijter JM, Islam S, Schnitzer J, Ellison AR, Tibboel D, Moorman AF, Lamers WH. Prenatal exposure to thyroid hormone is necessary for normal postnatal development of murine heart and lungs. *Dev Biol.* 2004 Aug 1; 272(1):104-17.